SCHEMBL24933348

SCHEMBL24933348

N#Cc1cccc(-c2cc(C(N)=O)c(=O)[nH]c2C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 1/20 0.47
IKBKB O14920 1/20 0.46
CHUK O15111 1/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.41
HSD17B1 P14061 3/20 0.41
HSD17B2 P37059 3/20 0.41
ALPL P05186 1/20 0.40
ALPI P09923 1/20 0.40
XDH P47989 2/20 0.39
PTPN5 P54829 1/20 0.39
SLC22A12 Q96S37 1/20 0.39
PARP1 P09874 2/20 0.38
CETP P11597 1/20 0.38
CHEK1 O14757 1/20 0.37
CSF1R P07333 1/20 0.37
PIN1 Q13526 1/20 0.37
PDK2 Q15119 1/20 0.37
MAPK8 P45983 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24933191 0.83 MMP3 (0.40) CDC7HSD17B1HSD17B2PARP1MAPK8
SCHEMBL24933186 0.83 HSD17B1 (0.44) HSD17B1HSD17B2PARP1
SCHEMBL24932959 0.83 HSD17B1 (0.44) IKBKBHSD17B1HSD17B2PARP1
SCHEMBL24933666 0.83 KCNH2 (0.48)
SCHEMBL24932950 0.82 HSD17B2 (0.52) CDC7IKBKBCHUKHSD17B1HSD17B2
SCHEMBL24933754 0.82 HSD17B2 (0.53) CDC7HSD17B1HSD17B2
SCHEMBL30896148 0.82 HSD17B2 (0.53) CDC7HSD17B1HSD17B2
SCHEMBL29203329 0.81 ADRA1D (0.40) CDC7IKBKBCHUKPTGDR2HSD17B1
SCHEMBL30240727 0.81 ADRA1D (0.40) CDC7IKBKBCHUKPTGDR2HSD17B1
SCHEMBL24933185 0.80 PARP1 (0.46) IKBKBCHUKHSD17B1HSD17B2PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2024-10-31 US claimed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP claimed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN claimed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO claimed
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2024-10-31 US disclosed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS PNPO, PDXK, PLPBP CDC7 1842/4885IKBKB 3308/4885CHUK 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.